Proto Axiom

The rounds this investor is named on, who it invests beside, and where it shows up.

Named on one round in the feed.

We build the companies we invest in.

Venture capitalSydney, Australiaprotoaxiom.comSince 2026-07-15

ROUNDS

joined, none as lead

ROUNDS JOINED · USD

$315M

across 1 round

LATEST ROUND

Series D · $315M · 2026-07-15

CO-INVESTORS

named beside it

Investor

The rounds this investor is named on, who it invests beside, and where it shows up.

AdvanCell is developing targeted alpha radiotherapies for cancer.

Series D$315M2026-07-156 [ REPORTED LATER ]

Company	Round	Amount	Announced	Role
AdvanCell AdvanCell is developing targeted alpha radiotherapies for cancer.	Series D Verified against 4 of 6 sources[ REPORTED LATER ]: This round was announced before Fireround first saw it. It stays in the company's history, not in Latest, Trending, or alerts.	$315M	2026-07-15	[ PART ]